PRN 211
Alternative Names: PRN-211Latest Information Update: 30 Aug 2023
At a glance
- Originator ProEn Therapeutics
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 20 Jul 2023 Early research in Solid tumours in South Korea (Parenteral) (ProEn Therapeutics pipeline, July 2023)